Dimed S.A. Distribuidora de Medicamentos
Dimed S.A. Distribuidora de Medicamentos sells medicines, perfumes, personal hygiene and beauty products, cosmetics, and dermo-cosmetics in Brazil. It sells its products through stores under Panvel brand. The company is also involved in purchasing, selling, brokering, subdividing, leasing, renting, managing and administering its owned and third-party properties. Dimed S.A. Distribuidora de Medica… Read more
Dimed S.A. Distribuidora de Medicamentos (PNVL3) - Net Assets
Latest net assets as of September 2025: R$1.26 Billion BRL
Based on the latest financial reports, Dimed S.A. Distribuidora de Medicamentos (PNVL3) has net assets worth R$1.26 Billion BRL as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$3.58 Billion) and total liabilities (R$2.32 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$1.26 Billion |
| % of Total Assets | 35.28% |
| Annual Growth Rate | 11.97% |
| 5-Year Change | 22.17% |
| 10-Year Change | 258.78% |
| Growth Volatility | 17.23 |
Dimed S.A. Distribuidora de Medicamentos - Net Assets Trend (2000–2024)
This chart illustrates how Dimed S.A. Distribuidora de Medicamentos's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dimed S.A. Distribuidora de Medicamentos (2000–2024)
The table below shows the annual net assets of Dimed S.A. Distribuidora de Medicamentos from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | R$1.23 Billion | +5.22% |
| 2023-12-31 | R$1.17 Billion | +5.89% |
| 2022-12-31 | R$1.11 Billion | +5.92% |
| 2021-12-31 | R$1.05 Billion | +3.52% |
| 2020-12-31 | R$1.01 Billion | +92.81% |
| 2019-12-31 | R$524.18 Million | +12.99% |
| 2018-12-31 | R$463.91 Million | +8.71% |
| 2017-12-31 | R$426.75 Million | +11.82% |
| 2016-12-31 | R$381.65 Million | +10.90% |
| 2015-12-31 | R$344.14 Million | +10.55% |
| 2014-12-31 | R$311.30 Million | +12.43% |
| 2013-12-31 | R$276.90 Million | +18.51% |
| 2012-12-31 | R$233.64 Million | +17.26% |
| 2011-12-31 | R$199.24 Million | +15.15% |
| 2010-12-31 | R$173.03 Million | +13.94% |
| 2009-12-31 | R$151.86 Million | +16.10% |
| 2008-12-31 | R$130.81 Million | +4.32% |
| 2007-12-31 | R$125.39 Million | +6.49% |
| 2006-12-31 | R$117.74 Million | +8.83% |
| 2005-12-31 | R$108.19 Million | +7.98% |
| 2004-12-31 | R$100.20 Million | +7.02% |
| 2003-12-31 | R$93.62 Million | +5.87% |
| 2002-12-31 | R$88.44 Million | +3.30% |
| 2001-12-31 | R$85.61 Million | +4.47% |
| 2000-12-31 | R$81.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dimed S.A. Distribuidora de Medicamentos's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 47663.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | R$273.68 Million | 22.17% |
| Common Stock | R$981.77 Million | 79.51% |
| Other Comprehensive Income | R$3.25 Million | 0.26% |
| Total Equity | R$1.23 Billion | 100.00% |
Dimed S.A. Distribuidora de Medicamentos Competitors by Market Cap
The table below lists competitors of Dimed S.A. Distribuidora de Medicamentos ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BankFirst Capital Corporation
OTCQX:BFCC
|
$166.44 Million |
|
MasterCraft Boat Holdings Inc
F:1SG
|
$166.47 Million |
|
Playtika Holding Corp
NASDAQ:PLTK
|
$166.49 Million |
|
Logan Energy Corp.
PINK:LOECF
|
$166.58 Million |
|
Anglo-Eastern Plantations Plc
PINK:AEPLF
|
$166.40 Million |
|
Contextlogic Inc
NASDAQ:LOGC
|
$166.37 Million |
|
Y.U.D. Yangtze River Investment Industry Co Ltd
SHG:600119
|
$166.34 Million |
|
Jiangsu Yitong High-tech Co Ltd
SHE:300211
|
$166.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dimed S.A. Distribuidora de Medicamentos's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,173,416,000 to 1,234,714,000, a change of 61,298,000 (5.2%).
- Net income of 105,509,000 contributed positively to equity growth.
- Dividend payments of 33,165,000 reduced retained earnings.
- Share repurchases of 4,929,000 reduced equity.
- New share issuances of 1,932,000 increased equity.
- Other comprehensive income decreased equity by 2,174,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$105.51 Million | +8.55% |
| Dividends Paid | R$33.16 Million | -2.69% |
| Share Repurchases | R$4.93 Million | -0.4% |
| Share Issuances | R$1.93 Million | +0.16% |
| Other Comprehensive Income | R$-2.17 Million | -0.18% |
| Other Changes | R$-5.88 Million | -0.48% |
| Total Change | R$- | 5.22% |
Book Value vs Market Value Analysis
This analysis compares Dimed S.A. Distribuidora de Medicamentos's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 20.33x to 1.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | R$0.72 | R$14.55 | x |
| 2005-12-31 | R$0.77 | R$14.55 | x |
| 2006-12-31 | R$0.84 | R$14.55 | x |
| 2007-12-31 | R$0.90 | R$14.55 | x |
| 2008-12-31 | R$0.94 | R$14.55 | x |
| 2009-12-31 | R$1.10 | R$14.55 | x |
| 2010-12-31 | R$1.25 | R$14.55 | x |
| 2011-12-31 | R$1.45 | R$14.55 | x |
| 2012-12-31 | R$1.71 | R$14.55 | x |
| 2013-12-31 | R$2.02 | R$14.55 | x |
| 2014-12-31 | R$2.28 | R$14.55 | x |
| 2015-12-31 | R$2.52 | R$14.55 | x |
| 2016-12-31 | R$2.79 | R$14.55 | x |
| 2017-12-31 | R$3.12 | R$14.55 | x |
| 2018-12-31 | R$3.40 | R$14.55 | x |
| 2019-12-31 | R$3.86 | R$14.55 | x |
| 2020-12-31 | R$6.67 | R$14.55 | x |
| 2021-12-31 | R$6.98 | R$14.55 | x |
| 2022-12-31 | R$7.43 | R$14.55 | x |
| 2023-12-31 | R$7.84 | R$14.55 | x |
| 2024-12-31 | R$8.21 | R$14.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dimed S.A. Distribuidora de Medicamentos utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.55%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.13%
- • Asset Turnover: 1.46x
- • Equity Multiplier: 2.74x
- Recent ROE (8.55%) is below the historical average (12.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 3.61% | 0.67% | 2.99x | 1.80x | R$-5.24 Million |
| 2001 | 8.13% | 1.56% | 2.85x | 1.83x | R$-1.60 Million |
| 2002 | 6.98% | 1.29% | 3.30x | 1.64x | R$-2.67 Million |
| 2003 | 10.71% | 1.88% | 3.10x | 1.84x | R$663.80K |
| 2004 | 11.47% | 1.98% | 3.22x | 1.80x | R$1.48 Million |
| 2005 | 11.80% | 1.97% | 2.98x | 2.01x | R$1.95 Million |
| 2006 | 12.23% | 1.96% | 3.13x | 1.99x | R$2.63 Million |
| 2007 | 11.30% | 1.70% | 3.29x | 2.02x | R$1.63 Million |
| 2008 | 7.41% | 1.04% | 3.38x | 2.11x | R$-3.39 Million |
| 2009 | 19.56% | 2.76% | 3.23x | 2.19x | R$14.51 Million |
| 2010 | 17.78% | 2.59% | 3.15x | 2.18x | R$13.47 Million |
| 2011 | 18.78% | 2.78% | 3.04x | 2.22x | R$17.50 Million |
| 2012 | 20.16% | 3.09% | 3.04x | 2.14x | R$23.74 Million |
| 2013 | 20.28% | 3.23% | 2.90x | 2.17x | R$28.46 Million |
| 2014 | 15.86% | 2.62% | 2.62x | 2.31x | R$18.23 Million |
| 2015 | 13.15% | 2.28% | 2.61x | 2.21x | R$10.85 Million |
| 2016 | 13.90% | 2.49% | 2.59x | 2.15x | R$14.89 Million |
| 2017 | 14.01% | 2.65% | 2.38x | 2.23x | R$17.12 Million |
| 2018 | 16.16% | 3.08% | 2.43x | 2.16x | R$28.59 Million |
| 2019 | 14.64% | 2.82% | 1.87x | 2.79x | R$24.34 Million |
| 2020 | 5.56% | 1.99% | 1.28x | 2.17x | R$-44.91 Million |
| 2021 | 7.59% | 2.46% | 1.35x | 2.28x | R$-25.19 Million |
| 2022 | 7.79% | 2.16% | 1.46x | 2.47x | R$-24.47 Million |
| 2023 | 7.92% | 2.08% | 1.45x | 2.62x | R$-24.44 Million |
| 2024 | 8.55% | 2.13% | 1.46x | 2.74x | R$-17.96 Million |
Industry Comparison
This section compares Dimed S.A. Distribuidora de Medicamentos's net assets metrics with peer companies in the Drug Manufacturers - General industry.
No peer company data available for comparison.